Adaptive immunity suppresses formation and progression of diethylnitrosamine-induced liver cancer
Carlo Schneider(RWTH Aachen University), Frank Tacke(Charité - Universitätsmedizin Berlin), Christian Trautwein(TUM Klinikum), Anja Hohmeyer(Medizinische Hochschule Hannover), Frank Staib(Johannes Gutenberg University Mainz), Sérgio A. Lira(Tisch Hospital), Lars Zender(German Cancer Research Center), Gudrun Walenda(RWTH Aachen University), Sebastian Huss(University Hospital Münster), Mihael Vucur(Düsseldorf University Hospital), Andreas Teufel(Johannes Gutenberg University Mainz), Tetyana Yevsa(Medizinische Hochschule Hannover), Henning W. Zimmermann(Sankt-Antonius-Hospital Eschweiler), Tom Luedde(Heinrich Heine University Düsseldorf), Hermann E. Wasmuth(Unknown), Nikolaus Gaßler(Ernst Abbe University of Applied Sciences Jena)
Cited by 179
Related Papers
EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
|Journal of Hepatology|2024|1.6k
Senescence surveillance of pre-malignant hepatocytes limits liver cancer development
|Nature|2011|1.6k
Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer
|Nature Medicine|2019|1.4k
Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis
|Hepatology|2010|786